Celldex Therapeutics Inc
$ 28.62
-4.38%
05 Jun - close price
- Market Cap 2,246,443,000 USD
- Current Price $ 28.62
- High / Low $ 30.05 / 28.46
- Stock P/E N/A
- Book Value 6.85
- EPS -4.27
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.31 %
- ROE -0.49 %
- 52 Week High 35.79
- 52 Week Low 19.52
About
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.
Analyst Target Price
$58.43
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-25 | 2025-11-10 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-06 | 2024-08-08 | 2024-05-06 | 2024-02-26 | 2023-11-02 | 2023-08-08 |
| Reported EPS | -1.18 | -1.22 | -1.01 | -0.85 | -0.81 | -0.71 | -0.64 | -0.54 | -0.56 | -0.83 | -0.81 | -0.65 |
| Estimated EPS | -1.13 | -1 | -0.89 | -0.84 | -0.74 | -0.7146 | -0.67 | -0.59 | -0.67 | -0.74 | -0.66 | -0.66 |
| Surprise | -0.05 | -0.22 | -0.12 | -0.01 | -0.07 | 0.0046 | 0.03 | 0.05 | 0.11 | -0.09 | -0.15 | 0.01 |
| Surprise Percentage | -4.4248% | -22% | -13.4831% | -1.1905% | -9.4595% | 0.6437% | 4.4776% | 8.4746% | 16.4179% | -12.1622% | -22.7273% | 1.5152% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLDX
2026-06-04 23:39:16
Celldex Therapeutics Inc. has successfully completed a $345 million public stock offering, selling 11,896,750 shares at $29.00 each, including the full exercise of the underwriters' option. This offering reflects a strong market return for the company and follows recent positive developments such as its Phase 2 trial results and an analyst upgrade. The biotechnology company aims to bolster its financial resources for developing antibody-based therapeutics.
2026-05-27 20:10:54
This article indicates a Schedule 13G/A filing for Celldex Therapeutics. This type of filing is typically made by an institutional investor or passive shareholder to report ownership of more than 5% of a company's stock, updating previous filings.
2026-05-15 20:10:12
Kynam Capital has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,840,567 shares of Celldex Therapeutics (CLDX), which represents an 8.77% stake in the company. The filing indicates shared voting and dispositive power for these shares among Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. The amendment confirms a passive investment intent, noting the ownership snapshot as of the filing date.
2026-05-15 18:10:12
Bellevue Group and its subsidiary, Bellevue Asset Management AG, have filed an Amendment No. 1 to their Schedule 13G/A for Celldex Therapeutics, Inc. (CLDX). This filing indicates that they now beneficially own 1.2 million shares, representing 1.5% of the common stock, a reduction that makes this an "exit filing" as their holdings are now below 5%. The report details their shared voting and dispositive power over these shares, calculating based on 78,492,072 shares outstanding.
2026-05-12 14:09:26
State Street Corporation has reported a beneficial ownership of 2,804,168 shares, representing a 4.2% stake in CELLDex Therapeutics. This disclosure, made via a Schedule 13G filing, indicates passive ownership and includes shared voting power over 2,620,053 shares and shared dispositive power over the full 2,804,168 shares. The filing lists several affiliated investment adviser entities as the reporting subsidiaries, confirming State Street's position as a large passive holder.
2026-05-11 13:39:39
Celldex Therapeutics reported a significant Q1 2026 loss of US$78.69 million with revenue falling to US$15,000, yet simultaneously advanced its lead antibody barzolvolimab, completing Phase 3 enrollment six months early and raising US$345 million. This mixed financial report and clinical progress are reshaping Celldex's investment outlook, with attention on late-2026 CSU readouts and the balance between dilution and extended funding. Investors are advised to consider various viewpoints on valuation and potential risks.
